UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 27, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 27, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 494 Common Stock at $511.58 ($252,718) on August 27, 2026; holds 333,449 after (Indirect).
- Open-market sale: disposed of 642 Common Stock at $512.47 ($329,007) on August 27, 2026; holds 332,807 after (Indirect).
- Open-market sale: disposed of 704 Common Stock at $513.40 ($361,434) on August 27, 2026; holds 332,103 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $514.32 ($61,718) on August 27, 2026; holds 331,983 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $515.33 ($123,679) on August 27, 2026; holds 331,743 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $517.07 ($144,780) on August 27, 2026; holds 331,463 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $518.89 ($103,779) on August 27, 2026; holds 331,263 after (Indirect).
- Open-market sale: disposed of 1,003 Common Stock at $520.23 ($521,795) on August 27, 2026; holds 330,260 after (Indirect).
- Open-market sale: disposed of 477 Common Stock at $521.24 ($248,629) on August 27, 2026; holds 329,783 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $522.40 ($146,273) on August 27, 2026; holds 329,503 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $523.60 ($125,664) on August 27, 2026; holds 329,263 after (Indirect).
- Open-market sale: disposed of 744 Common Stock at $524.61 ($390,310) on August 27, 2026; holds 328,519 after (Indirect).
- Open-market sale: disposed of 376 Common Stock at $525.62 ($197,632) on August 27, 2026; holds 328,143 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $526.37 ($147,385) on August 27, 2026; holds 327,863 after (Indirect).
- Open-market sale: disposed of 1,237 Common Stock at $528.29 ($653,500) on August 27, 2026; holds 326,626 after (Indirect).
- Open-market sale: disposed of 1,308 Common Stock at $529.15 ($692,128) on August 27, 2026; holds 325,318 after (Indirect).
- Open-market sale: disposed of 755 Common Stock at $530.08 ($400,210) on August 27, 2026; holds 324,563 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $531.12 ($63,734) on August 27, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on August 27, 2026; holds 46,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,964,376 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-08-27 | Open-market sale | Common Stock | 494 | $512 | $252.7K | 333,449 |
| 2026-08-27 | Open-market sale | Common Stock | 642 | $512 | $329.0K | 332,807 |
| 2026-08-27 | Open-market sale | Common Stock | 704 | $513 | $361.4K | 332,103 |
| 2026-08-27 | Open-market sale | Common Stock | 120 | $514 | $61.7K | 331,983 |
| 2026-08-27 | Open-market sale | Common Stock | 240 | $515 | $123.7K | 331,743 |
| 2026-08-27 | Open-market sale | Common Stock | 280 | $517 | $144.8K | 331,463 |
| 2026-08-27 | Open-market sale | Common Stock | 200 | $519 | $103.8K | 331,263 |
| 2026-08-27 | Open-market sale | Common Stock | 1,003 | $520 | $521.8K | 330,260 |
| 2026-08-27 | Open-market sale | Common Stock | 477 | $521 | $248.6K | 329,783 |
| 2026-08-27 | Open-market sale | Common Stock | 280 | $522 | $146.3K | 329,503 |
| 2026-08-27 | Open-market sale | Common Stock | 240 | $524 | $125.7K | 329,263 |
| 2026-08-27 | Open-market sale | Common Stock | 744 | $525 | $390.3K | 328,519 |
| 2026-08-27 | Open-market sale | Common Stock | 376 | $526 | $197.6K | 328,143 |
| 2026-08-27 | Open-market sale | Common Stock | 280 | $526 | $147.4K | 327,863 |
| 2026-08-27 | Open-market sale | Common Stock | 1,237 | $528 | $653.5K | 326,626 |
| 2026-08-27 | Open-market sale | Common Stock | 1,308 | $529 | $692.1K | 325,318 |
| 2026-08-27 | Open-market sale | Common Stock | 755 | $530 | $400.2K | 324,563 |
| 2026-08-27 | Open-market sale | Common Stock | 120 | $531 | $63.7K | 324,443 |
| 2026-08-27 | Option exercise/conversion | Stock Option | 9,500 | — | — | 46,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Option exercise/conversion (9,500 shares) |
| 2026-08-27 | Open-market sale (494 shares) |
| 2026-08-27 | Open-market sale (642 shares) |
| 2026-08-27 | Open-market sale (704 shares) |
| 2026-08-27 | Open-market sale (120 shares) |
| 2026-08-27 | Open-market sale (240 shares) |
| 2026-08-27 | Open-market sale (280 shares) |
| 2026-08-27 | Open-market sale (200 shares) |
| 2026-08-27 | Open-market sale (1,003 shares) |
| 2026-08-27 | Open-market sale (477 shares) |
| 2026-08-27 | Open-market sale (280 shares) |
| 2026-08-27 | Open-market sale (240 shares) |
| 2026-08-27 | Open-market sale (744 shares) |
| 2026-08-27 | Open-market sale (376 shares) |
| 2026-08-27 | Open-market sale (280 shares) |
| 2026-08-27 | Open-market sale (1,237 shares) |
| 2026-08-27 | Open-market sale (1,308 shares) |
| 2026-08-27 | Open-market sale (755 shares) |
| 2026-08-27 | Open-market sale (120 shares) |
| 2026-08-27 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.